Hiroshi M Kiyono, 677465 Mermaid Ln, Carlsbad, CA 92011
Hiroshi Kiyono Phones & Addresses
Carlsbad, CA
Hoover, AL
Mentions for Hiroshi M Kiyono
Publications & IP owners
Us Patents
Oral Administration Of Pneumoccal Antigens
US Patent:
6231870, May 15, 2001
Filed:
Jun 2, 1995
Appl. No.:
8/458399
Inventors:
David E. Briles - Birmingham AL
Larry S. McDaniel - Ridgeland MS
Masafumi Yamamoto - Birmingham AL
Hiroshi Kiyono - Birmingham AL
Larry S. McDaniel - Ridgeland MS
Masafumi Yamamoto - Birmingham AL
Hiroshi Kiyono - Birmingham AL
Assignee:
UAB Research Foundation - Birmingham AL
International Classification:
A61K 3909
C12N 1500
C12N 120
C12N 1500
C12N 120
US Classification:
4242441
Abstract:
Oral or peroral administration, including intragastrically, of killed whole pneumococci, lysate of pneumococci and isolated and purified PspA, as well as immunogenic fragments thereof, particularly when administered with an adjuvant such as cholera toxin provides protection in a host, animal or human, against pneumococcal infection, including colonization, and systemic infection, such as sepsis. The ability to elicit protection against pneumococcal colonization in a host prevents carriage among immunized individuals, which can lead to elimination of disease from the population as a whole.
Oral Administration Of Pneumococcal Antigens
US Patent:
6004802, Dec 21, 1999
Filed:
May 30, 1996
Appl. No.:
8/657751
Inventors:
David E. Briles - Birmingham AL
Larry S. McDaniel - Ridgeland MS
Masafumi Yamamoto - Birmingham AL
Hiroshi Kiyono - Birmingham AL
Larry S. McDaniel - Ridgeland MS
Masafumi Yamamoto - Birmingham AL
Hiroshi Kiyono - Birmingham AL
Assignee:
University of Alabama at Birmingham - Birmingham AL
International Classification:
C12N 1500
A61K 3909
A61K 3909
US Classification:
4353201
Abstract:
Oral or peroral administration, including intragastrically, of killed whole pneumococci, lysate of pneumococci and isolated and purified PspA, as well as immunogenic fragments thereof, particularly when administered with an adjuvant such as cholera toxin provides protection in a host, animal or human, against pneumococcal infection, including colonization, and systemic infection, such as sepsis. The ability to elicit protection against pneumococcal colonization in a host prevents carriage among immunized individuals, which can lead to elimination of disease from the population as a whole.
Oral Administration Of Pneumococcal Antigens
US Patent:
6232116, May 15, 2001
Filed:
Jun 7, 1995
Appl. No.:
8/482981
Inventors:
David E. Briles - Birmingham AL
Larry S. McDaniel - Ridgeland MS
Masafumi Yamamoto - Birmingham AL
Hiroshi Kiyono - Birmingham AL
Larry S. McDaniel - Ridgeland MS
Masafumi Yamamoto - Birmingham AL
Hiroshi Kiyono - Birmingham AL
Assignee:
University of Alabama at Birmingham Research Foundation - Birmingham AL
International Classification:
A61K 3909
C12N 1500
C12N 1500
US Classification:
4353201
Abstract:
Oral or peroral administration, including intragastrically, of killed whole pneumococci, lysate of pneumococci and isolated and purified PspA, as well as immunogenic fragments thereof, particularly when administered with an adjuvant such as cholera toxin provides protection in a host, animal or human, against pneumococcal infection, including colonization, and systemic infection, such as sepsis. The ability to elicit protection against pneumococcal colonization in a host prevents carriage among immunized individuals, which can lead to elimination of disease from the population as a whole.
Isbn (Books And Publications)
Essentials Of Mucosal Immunology
Author:
Hiroshi Kiyono
ISBN #:
0123943302
Mucosal Immunology: Intraepithelial Lymphocytes
Author:
Hiroshi Kiyono
ISBN #:
0781701171
NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.